Reactivity to type I interferon is key to predict cancer immunotherapy response View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-07-25

ABSTRACT

The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.

PAGES

1146-1147

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z

DOI

http://dx.doi.org/10.1038/s41590-022-01278-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149723766

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35879452


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon Type I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41590-021-00975-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1139927264", 
          "https://doi.org/10.1038/s41590-021-00975-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-07-25", 
    "datePublishedReg": "2022-07-25", 
    "description": "The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41590-022-01278-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1022778", 
        "issn": [
          "1529-2908", 
          "1529-2916"
        ], 
        "name": "Nature Immunology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "effector CD4 T cells", 
      "cancer immunotherapy response", 
      "immune checkpoint inhibition", 
      "CD4 T cells", 
      "overall survival", 
      "treatment initiation", 
      "checkpoint inhibition", 
      "immunotherapy response", 
      "T cells", 
      "I interferon", 
      "therapeutic efficacy", 
      "patients", 
      "interferon", 
      "cancer", 
      "response", 
      "efficacy", 
      "survival", 
      "responsiveness", 
      "inhibition", 
      "cells", 
      "initiation", 
      "reactivity", 
      "features", 
      "relevant features", 
      "deterministic"
    ], 
    "name": "Reactivity to type I interferon is key to predict cancer immunotherapy response", 
    "pagination": "1146-1147", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149723766"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41590-022-01278-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35879452"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41590-022-01278-z", 
      "https://app.dimensions.ai/details/publication/pub.1149723766"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_937.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41590-022-01278-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z'


 

This table displays all metadata directly associated to this object as RDF triples.

99 TRIPLES      20 PREDICATES      55 URIs      45 LITERALS      10 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41590-022-01278-z schema:about N0b904af2a56b428799ec5e2a364ec59a
2 N67a04a4e2ccc434a9b29e446a3f307fc
3 Nbd960924ad764045b7bc4b96d10e96f6
4 Nd0c084fc8783423b97f699e3ff664223
5 anzsrc-for:11
6 anzsrc-for:1107
7 anzsrc-for:1112
8 schema:citation sg:pub.10.1038/s41590-021-00975-5
9 schema:datePublished 2022-07-25
10 schema:datePublishedReg 2022-07-25
11 schema:description The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.
12 schema:genre article
13 schema:isAccessibleForFree false
14 schema:isPartOf N536860c16fe74b61b1d7c61780f4d08a
15 Nf71778bc145d48af82c67ec62ba227ab
16 sg:journal.1022778
17 schema:keywords CD4 T cells
18 I interferon
19 T cells
20 cancer
21 cancer immunotherapy response
22 cells
23 checkpoint inhibition
24 deterministic
25 effector CD4 T cells
26 efficacy
27 features
28 immune checkpoint inhibition
29 immunotherapy response
30 inhibition
31 initiation
32 interferon
33 overall survival
34 patients
35 reactivity
36 relevant features
37 response
38 responsiveness
39 survival
40 therapeutic efficacy
41 treatment initiation
42 schema:name Reactivity to type I interferon is key to predict cancer immunotherapy response
43 schema:pagination 1146-1147
44 schema:productId N5258826dfe85453eb0227962ede22626
45 N78387adca9da44b3b1be1e6061ef9053
46 Nc057b215053448748b3441a536e55f14
47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149723766
48 https://doi.org/10.1038/s41590-022-01278-z
49 schema:sdDatePublished 2022-10-01T06:50
50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
51 schema:sdPublisher N95cfb80a12e74016adcdde7c6892e9a9
52 schema:url https://doi.org/10.1038/s41590-022-01278-z
53 sgo:license sg:explorer/license/
54 sgo:sdDataset articles
55 rdf:type schema:ScholarlyArticle
56 N0b904af2a56b428799ec5e2a364ec59a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Neoplasms
58 rdf:type schema:DefinedTerm
59 N5258826dfe85453eb0227962ede22626 schema:name pubmed_id
60 schema:value 35879452
61 rdf:type schema:PropertyValue
62 N536860c16fe74b61b1d7c61780f4d08a schema:volumeNumber 23
63 rdf:type schema:PublicationVolume
64 N67a04a4e2ccc434a9b29e446a3f307fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Interferon Type I
66 rdf:type schema:DefinedTerm
67 N78387adca9da44b3b1be1e6061ef9053 schema:name dimensions_id
68 schema:value pub.1149723766
69 rdf:type schema:PropertyValue
70 N95cfb80a12e74016adcdde7c6892e9a9 schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 Nbd960924ad764045b7bc4b96d10e96f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Immunotherapy
74 rdf:type schema:DefinedTerm
75 Nc057b215053448748b3441a536e55f14 schema:name doi
76 schema:value 10.1038/s41590-022-01278-z
77 rdf:type schema:PropertyValue
78 Nd0c084fc8783423b97f699e3ff664223 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Humans
80 rdf:type schema:DefinedTerm
81 Nf71778bc145d48af82c67ec62ba227ab schema:issueNumber 8
82 rdf:type schema:PublicationIssue
83 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
84 schema:name Medical and Health Sciences
85 rdf:type schema:DefinedTerm
86 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
87 schema:name Immunology
88 rdf:type schema:DefinedTerm
89 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
90 schema:name Oncology and Carcinogenesis
91 rdf:type schema:DefinedTerm
92 sg:journal.1022778 schema:issn 1529-2908
93 1529-2916
94 schema:name Nature Immunology
95 schema:publisher Springer Nature
96 rdf:type schema:Periodical
97 sg:pub.10.1038/s41590-021-00975-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139927264
98 https://doi.org/10.1038/s41590-021-00975-5
99 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...